<DOC>
	<DOCNO>NCT00680225</DOCNO>
	<brief_summary>To report preliminary result safety tolerability intravitreal injection Ranibizumab ( Lucentis ) combine Transpupillary Thermotherapy ( TTT ) + Indocyanine Green ( ICG ) -based photodynamic therapy ( PDT ) treatment choroidal melanoma .</brief_summary>
	<brief_title>Lucentis Adjuvant Therapy With TTT-ICG Based Choroidal Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Age &gt; 18 yo . Primary pigment amelanotic choroidal melanoma measurement 16 mm less large vessel diameter 6 mm less apical height . Location tumor posterior equator . Documented growth A/B scan . Risk factor metastasis ( thickness great 2 mm , symptom , tumor margin optic disc ) Ability provide inform consent . Comply study assessment cooperation study . Pregnancy lactation . Premenopausal woman use adequate contraception ; surgical sterilization use oral contraception , barrier contraception either condom diaphragm conjunction spermicidal gel , IUD contraceptive hormon implant patch . Current infection inflammation either eye . Extension tumor orbit . Retinal spread metastatic disease . Any condition investigator believe would pose significant hazard subject investigational therapy initiate . Any known allergy component use study . Participation another simultaneous medical investigation trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Choroidal melanoma</keyword>
	<keyword>Lucentis</keyword>
	<keyword>TTT-ICG</keyword>
</DOC>